{
  "id": 1522,
  "text": "9 9 3 } }$ $9 5 \\% \\mathrm { C I } \\ =$ 1.018-15.67), $\\mathrm { p } = 0 .0 4 7 \\mathrm { \\ : ] }$ ).It should be noted that (1) the advantages in terms of 5-year OS, DFS and local relapse-free survival in favor of patients treated with thermochemoradiotherapy compared to those who underwent chemoradiotherapy did not reach statistical significance and (2) the addition of hyperthermia was well tolerated and caused no additional acute or long-term toxicity compared with chemoradiotherapy alone.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 9 9 3 } }$ $9 5 \\% \\mathrm { C I } \\ =$ 1.018-15.67), $\\mathrm { p } = 0 .0 4 7 \\mathrm { \\ : ] }$ ).It should be noted that (1) the advantages in terms of 5-year OS, DFS and local relapse-free survival in favor of patients treated with thermochemoradiotherapy compared to those who underwent chemoradiotherapy did not reach statistical significance and (2) the addition of hyperthermia was well tole\n\n<question>: ",
  "ChatGPT_response_0": "根据研究结果显示，接受热化疗放疗的患者和接受化疗放疗的患者之间在生存率和局部复发方面并未表现出明显的差异。研究指出，在5年生存率、无疾病生存率和局部复发无病生存率方面，热化疗放疗并没有明显优势。同时，添加热疗在耐受性方面表现良好，并未引起额外的急性或长期毒性，与仅进行化疗放疗相比并无明显差异。",
  "query": "对于接受热化疗放疗的患者和接受化疗放疗的患者之间的生存率和局部复发无差异是否显著？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 对于接受热化疗放疗的患者和接受化疗放疗的患者之间的生存率和局部复发无差异是否显著？\n\n<reference text>: 9 9 3 } }$ $9 5 \\% \\mathrm { C I } \\ =$ 1.018-15.67), $\\mathrm { p } = 0 .0 4 7 \\mathrm { \\ : ] }$ ).It should be noted that (1) the advantages in terms of 5-year OS, DFS and local relapse-free survival in favor of patients treated with thermochemoradiotherapy compared to those who underwent chemoradiotherapy did not reach statistical significance and (2) the addition of hyperthermia was well tolerated and caused no additional acute or long-term toxicity compared with chemoradiotherapy alone.\n\n<reply>: ",
  "response": "根据研究结果显示，接受热化疗放疗的患者和接受化疗放疗的患者之间在生存率和局部复发方面并未表现出明显的差异。研究指出，在5年生存率、无疾病生存率和局部复发无病生存率方面，热化疗放疗并没有明显优势。同时，添加热疗在耐受性方面表现良好，并未引起额外的急性或长期毒性，与仅进行化疗放疗相比并无明显差异。"
}